I 
117TH CONGRESS 
2D SESSION 
H. R. 7750 
To amend the Public Health Service Act to establish a Prostate Cancer 
Coordinating Committee, and for other purposes. 
IN THE HOUSE OF REPRESENTATIVES 
MAY 12, 2022 
Mr. MURPHY of North Carolina (for himself and Mr. RUSH) introduced the 
following bill; which was referred to the Committee on Energy and Commerce 
A BILL 
To amend the Public Health Service Act to establish a Pros-
tate Cancer Coordinating Committee, and for other pur-
poses. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Prostate Cancer Com-
munity Assistance, Research and Education Act of 2022’’ 
or the ‘‘PC–CARE Act’’. 
SEC. 2. FINDINGS. 
Congress finds the following: 
(1) Prostate cancer is the most commonly diag-
nosed non-skin cancer and the second leading cause 
VerDate Sep 11 2014 
18:52 May 24, 2022
Jkt 029200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H7750.IH
H7750
pamtmann on DSKBC07HB2PROD with BILLS
of cancer-related deaths among men in the United 
States. 
(2) Over 3,100,000 men in the United States 
live with a prostate cancer diagnosis and it is esti-
mated that in 2021, 248,530 men will be diagnosed 
with, and more than 34,130 men will die of, prostate 
cancer. 
(3) Men with at least one close relative who has 
been diagnosed with prostate cancer have twice the 
risk of having prostate cancer compared to the gen-
eral population. 
(4) At least 12 percent of men with metastatic 
prostate cancer have inherited predispositions to the 
disease and potentially actionable genomic alter-
ations have been identified in over 90 percent of 
men with metastatic castration-resistant prostate 
cancer. 
(5) Advances in science to identify, test, and 
treat these men at increased genetic risk of disease 
are needed. 
(6) African-American men suffer from a pros-
tate cancer incidence rate that is significantly higher 
than that of White men and have more than double 
the prostate cancer mortality rate than that of 
White men. 
VerDate Sep 11 2014 
18:52 May 24, 2022
Jkt 029200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H7750.IH
H7750
pamtmann on DSKBC07HB2PROD with BILLS
Health and Health Disparities, and the Clinical Cen-
ter. 
(13) Additional agencies and offices within the 
Department of Health and Human Services conduct 
activities related to prostate cancer, including the 
Centers for Medicare and Medicaid Services, the 
Centers for Disease Control and Prevention, the 
Food and Drug Administration, the Health Re-
sources and Services Administration, the Office of 
Minority Health, and the Agency for Healthcare Re-
search and Quality. 
(14) The Department of Defense created the 
Prostate Cancer Research Program in 1997 and has 
funded more than $2,000,000,000 in prostate cancer 
research since that time. 
(15) Private foundations have provided substan-
tial funding to the prostate cancer research commu-
nity for almost three decades, including support for 
over 200 cancer centers and universities. 
(16) The Director of the National Institutes of 
Health has partnered with private prostate cancer 
research groups to study to study biological and 
nonbiological factors associated aggressive prostate 
cancer in African-American men. 
VerDate Sep 11 2014 
18:52 May 24, 2022
Jkt 029200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H7750.IH
H7750
pamtmann on DSKBC07HB2PROD with BILLS
(17) The Secretary of Veterans Affairs has 
partnered with private foundations to establish pre-
cision oncology program hubs for prostate cancer. 
(18) The Director of the Centers for Disease 
Control and Prevention has partnered with multiple 
private stakeholder groups to increase awareness 
and education around prostate cancer in the general 
population and among high-risk groups. 
(19) Increased coordination of governmental 
and nongovernmental activities can reduce costs and 
increase effectiveness of ongoing work. 
(20) Joint planning and goal setting across the 
Government and private sector can create a pathway 
toward eliminating prostate cancer deaths and im-
proving care for millions of men. 
SEC. 3. PROSTATE CANCER COORDINATING COMMITTEE. 
Part A of title IV of the Public Health Service Act 
(42 U.S.C. 281 et seq.) is amended by adding at the end 
the following: 
‘‘SEC. 404F. PROSTATE CANCER COORDINATING COM-
MITTEE. 
‘‘(a) ESTABLISHMENT.—The Secretary shall estab-
lish a committee to be known as the Prostate Cancer Co-
ordinating Committee (referred to in this section as the 
‘Coordinating Committee’). 
VerDate Sep 11 2014 
18:52 May 24, 2022
Jkt 029200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6201
E:\BILLS\H7750.IH
H7750
pamtmann on DSKBC07HB2PROD with BILLS
‘‘(b) DUTIES.—The Coordinating Committee shall— 
‘‘(1) monitor, coordinate, and evaluate activities 
with respect to prostate cancer research programs 
carried out by Federal agencies; and 
‘‘(2) develop and implement the plan under sub-
section (g). 
‘‘(c) COMPOSITION.— 
‘‘(1) IN
GENERAL.—The Coordinating Com-
mittee shall be composed of not more than 24 mem-
bers, to be appointed by the Secretary, of whom— 
‘‘(A) one-half shall represent Federal agen-
cies that carry out research or treatment activi-
ties with respect to prostate cancer, including— 
‘‘(i) the Director of the National In-
stitutes of Health (or designee); 
‘‘(ii) the directors of the appropriate 
agencies of the National Institutes of 
Health (or designees), including the Na-
tional Cancer Institute; 
‘‘(iii) the Director of the Centers for 
Disease Control and Prevention (or des-
ignee); 
‘‘(iv) the Administrator of the Health 
Resources and Services Administration (or 
designee); 
VerDate Sep 11 2014 
18:52 May 24, 2022
Jkt 029200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6201
E:\BILLS\H7750.IH
H7750
pamtmann on DSKBC07HB2PROD with BILLS
‘‘(v) the Administrator of the Centers 
for Medicare & Medicaid Services (or des-
ignee); 
‘‘(vi) the Commissioner of Food and 
Drugs (or designee); 
‘‘(vii) the Secretary of Defense (or 
designee); and 
‘‘(viii) the Secretary of Veterans Af-
fairs (or designee); and 
‘‘(B) one-half shall be individuals who have 
experience with prostate cancer, including— 
‘‘(i) not less than 3 individuals who 
are living with prostate cancer (or a care-
giver of such individual); 
‘‘(ii) not less than 3 researchers; 
‘‘(iii) not less than 3 clinicians; 
‘‘(iv) not less than 3 representatives 
from patient groups; and 
‘‘(v) not less than 3 representatives 
from professional medical societies. 
‘‘(2) PHYSICIAN REQUIREMENT.—Of the mem-
bers appointed under paragraph (1), not less than 
one-half shall be physicians. 
‘‘(d) TERM; VACANCIES.— 
VerDate Sep 11 2014 
18:52 May 24, 2022
Jkt 029200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6201
E:\BILLS\H7750.IH
H7750
pamtmann on DSKBC07HB2PROD with BILLS
‘‘(1) IN
GENERAL.—A member shall be ap-
pointed for a term of 3 years. 
‘‘(2) VACANCIES.—A vacancy on the Coordi-
nating Committee shall be filled in the same manner 
as the original appointment was made. 
‘‘(e) REAPPOINTMENT.—The Secretary may re-
appoint a member of the Coordinating Committee to an 
unlimited number of terms. 
‘‘(f) CHAIR.—The Secretary shall appoint the chair 
of the Coordinating Committee. 
‘‘(g) PLAN.—Not later than 1 year after the date of 
the enactment of this section, the Coordinating Committee 
shall develop and implement a plan (and update such plan 
every 3 years thereafter), in consultation with a broad 
range of scientists, patients, clinicians, and advocacy 
groups, on prostate cancer research programs and activi-
ties carried out by Federal agencies. Such plan shall in-
clude the following: 
‘‘(1) The identification of existing prostate can-
cer programs and activities of the— 
‘‘(A) the Department of Health and 
Human Services, including the National Insti-
tutes of Health; 
‘‘(B) the Department of Defense; and 
‘‘(C) the Department of Veterans Affairs. 
VerDate Sep 11 2014 
18:52 May 24, 2022
Jkt 029200
PO 00000
Frm 00008
Fmt 6652
Sfmt 6201
E:\BILLS\H7750.IH
H7750
pamtmann on DSKBC07HB2PROD with BILLS
‘‘(2) An evaluation on research with respect to 
the underlying causes, prevalence, treatment, and 
mortality of prostate cancer, including any disparity 
among African-American and other high-risk men 
(defined as men who have a family history of pros-
tate cancer, a genetic predisposition for prostate 
cancer, or developed cancer due to exposure to cer-
tain chemical and radiological agents). 
‘‘(3) With respect to prostate cancer— 
‘‘(A) an evaluation on the effectiveness of 
current screening and diagnostic techniques; 
and 
‘‘(B) recommendations for improving such 
techniques. 
‘‘(4) An evaluation on the effectiveness of treat-
ments for prostate cancer and the development of 
recommendations for new treatments, including new 
biological agents. 
‘‘(5) With respect to prostate cancer, an evalua-
tion on the effectiveness of clinical practice guide-
lines and the development of recommendations to 
improve such guidelines. 
‘‘(6) The development of recommendations to 
improve clinical pathways in private and govern-
ment-operated medical systems, including screening 
VerDate Sep 11 2014 
18:52 May 24, 2022
Jkt 029200
PO 00000
Frm 00009
Fmt 6652
Sfmt 6201
E:\BILLS\H7750.IH
H7750
pamtmann on DSKBC07HB2PROD with BILLS
and diagnosis and information on informed and 
shared decision making. 
‘‘(7) The development of recommendations for 
research investigation methods for improving the 
quality of life of individuals who have survived with 
prostate cancer. 
‘‘(8) With respect to prostate cancer, an evalua-
tion on the effectiveness of information and edu-
cation programs for health care professionals and 
the public. 
‘‘(9) With respect to screening and clinical trial 
enrollment for prostate cancer, recommendations to 
improve outreach and education, including best prac-
tices for outreach to African-American men and 
other high-risk men. 
‘‘(h) MEETINGS.—The Coordinating Committee shall 
meet at the request of the Secretary not less 3 times each 
year. 
‘‘(i) FACA.—Except as provided in this section, the 
Federal Advisory Committee Act (5 U.S.C. App.) shall not 
apply to the Coordinating Committee. 
‘‘(j) REPORT.— 
‘‘(1) INITIAL REPORT.—Not later than 1 year 
after the date of the enactment of this section, the 
Coordinating Committee shall submit recommenda-
VerDate Sep 11 2014 
18:52 May 24, 2022
Jkt 029200
PO 00000
Frm 00010
Fmt 6652
Sfmt 6201
E:\BILLS\H7750.IH
H7750
pamtmann on DSKBC07HB2PROD with BILLS
tions using the plan under subsection (g) to the fol-
lowing: 
‘‘(A) The Secretary of the Department of 
Health and Human Services. 
‘‘(B) The Secretary of Defense. 
‘‘(C) The Secretary of Veterans Affairs. 
‘‘(D) The Committees on Energy and 
Commerce and Appropriations of the House of 
Representatives. 
‘‘(E) The Committees on Health, Edu-
cation, Labor, and Pensions and Appropriations 
of the Senate. 
‘‘(2) UPDATED
REPORTS.—Not later than 3 
years after the date of the enactment of this section, 
and every 3 years thereafter, the Coordinating Com-
mittee shall submit to the secretaries and commit-
tees listed in paragraph (1)— 
‘‘(A) updated recommendations using the 
plan under subsection (g); and 
‘‘(B) a summary of progress made with re-
spect to recommendations submitted pursuant 
to this section. 
‘‘(k) AUTHORIZATION OF APPROPRIATIONS.—There 
are authorized to be appropriated to carry out this section 
VerDate Sep 11 2014 
18:52 May 24, 2022
Jkt 029200
PO 00000
Frm 00011
Fmt 6652
Sfmt 6201
E:\BILLS\H7750.IH
H7750
pamtmann on DSKBC07HB2PROD with BILLS
such sums as may be necessary for each of fiscal years 
2023 through 2029.’’. 
Æ 
VerDate Sep 11 2014 
18:52 May 24, 2022
Jkt 029200
PO 00000
Frm 00012
Fmt 6652
Sfmt 6301
E:\BILLS\H7750.IH
H7750
pamtmann on DSKBC07HB2PROD with BILLS